BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.
infoBioLife Solutions is a small cap stock with a total market cap of 489.70M.
infoThey trade on the NASDAQ and had their IPO 33 years and 9 months ago.
infoBioLife Solutions currently employs 466 people.
infoAs of Wednesday, Aug 23 2023, BioLife Solutions’s share price is $11.26.
News Relating to BioLife Solutions
The Motley Fool
Why Shares of BioLife Solutions Plummeted This Week
Friday Aug 11 2023 at 16:06
BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter.
The Motley Fool
Why Shares of BioLife Solutions Are Slumping on Wednesday
Wednesday Aug 09 2023 at 13:38
BioLife Solutions said it is divesting itself of some assets to focus on its higher-margin business. The company saw declining revenue but narrowed its losses dramatically.
Zacks Investment Research
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates
Tuesday Aug 08 2023 at 19:41
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago.
GuruFocus
Atrion Corp (ATRI): A Medical Device Stock with Good Outperformance Potential
Tuesday Aug 08 2023 at 15:03
Atrion Corp ( ATRI , Financial), a leading player in the Medical Devices & Instruments industry, is currently trading at $557 per share. The company has a market capitalization of $980.596 million and has seen a stock price gain of 4.7% today.
GuruFocus
EVP & Chief Scientific Officer Aby Mathew Sells 20,000 Shares of BioLife Solutions Inc (BLFS)
Saturday May 27 2023 at 14:23
On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 shares of the company’s stock. This recent transaction is part of a series of insider sales by Mathew over the past year, totaling 111,135 shares sold and no shares purchased.
GuruFocus
EVP & Chief Scientific Officer Aby Mathew Sells 20,000 Shares of BioLife Solutions Inc
Friday May 26 2023 at 14:17
On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 shares of the company’s stock. This recent transaction is part of a broader trend of insider selling at BioLife Solutions Inc, which we will analyze in this article.
Seeking Alpha
BioLife Solutions, Inc. (BLFS) Q1 2023 Earnings Call Transcript
Wednesday May 10 2023 at 21:30
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Troy Wichterman – CFO Michael Rice – Chairman & CEO Conference Call Participants Jacob Johnson – Stephens Inc. Thomas Flaten – Lake Street Capital Markets Chad Wiatrowski – TD Cowen Carl Byrnes – Northland Capital Markets Yuan Zhi – B. Riley Securities Paul Knight – KeyBanc Capital Markets Operator Hello.
Zacks Investment Research
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates
Wednesday May 10 2023 at 18:59
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.
Seeking Alpha
BioLife Solutions: Capitalizing On The Future Of Biopreservation
Tuesday Mar 28 2023 at 12:08
BioLife Solutions, a leading provider of bioproduction tools and services, is poised for growth as the demand for biologics and regenerative medicine increases. CryoStor and HypoThermosol have shown significant improvement to the post-preservation viability of biologic materials during manufacturing, storage, and distribution.
Seeking Alpha
BioLife Solutions Is Set To Finally Absorb Its Acquisitions
Saturday Mar 25 2023 at 07:51
An acquisition spree has produced a host of problems, costs, write-offs, a collapse in gross margins and profits, cash bleed, and significant dilution. While only the evo and Sexton acquisitions have been a real success, the problems at some of the others now seem to be largely in the rearview mirror.
Seeking Alpha
BioLife Solutions, Inc. (BLFS) Q4 2022 Earnings Call Transcript
Thursday Mar 16 2023 at 21:55
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Yuan Zhi – B. Riley Thomas Flaten – Lake Street Operator Good day, and welcome to the BioLife Solutions’ Fourth Quarter 2022 and Full Year Earnings Call.
PRNewsWire
BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences
Tuesday Jan 17 2023 at 08:04
BOTHELL, Wash. , Jan. 17, 2023 /PRNewswire/ — BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced the dates of its 2023 analyst day and upcoming investor conferences where management will be presenting and meeting with current and prospective investors.
Seeking Alpha
BioLife Solutions: Inventory Movement A Key Benchmarking Factor, Retain Hold
Thursday Jan 05 2023 at 17:00
BioLife Solutions, Inc. guidance narrowed for full-year estimates, whilst there were several observable challenges exhibited in Q3 numbers. It could be a while before the company returns back to profitability, hence, the investment and valuation metrics don’t stack up at present.
PRNewsWire
BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023
Monday Dec 19 2022 at 08:03
Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL, Wash.
Seeking Alpha
BioLife Solutions, Inc. (BLFS) Q3 2022 Earnings Call Transcript
Wednesday Nov 09 2022 at 22:08
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman & Chief Executive Officer Rod de Greef – President & Chief Operating Officer Conference Call Participants Paul Knight – KeyBanc Thomas Flaten – Lake Street Jacob Johnson – Stephens Stephanie Iannetta – Cowen and Company Yuan Zhi – B. Riley Securities Suraj Kalia – Oppenheimer Operator Good afternoon, ladies and gentlemen and thank you for standing by.
Zacks Investment Research
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates
Wednesday Nov 09 2022 at 19:34
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
BioLife: What The Future Holds
Wednesday Oct 19 2022 at 08:33
BioLife recently formed a strategic partnership with CSafe to expand its service repertoire for its customers. The latest quarter reported extremely strong growth across all operations.
Seeking Alpha
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 09 2022 at 21:40
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Rod de Greef – President and Chief Operating Officer Conference Call Participants Thomas Flaten – Lake Street Capital Markets Hannah Hefley – Stephens Max Masucci – Cowen and Company Suraj Kalia – Oppenheimer Operator Good day. My name is Chantel, and I’ll be your conference operator today.
Zacks Investment Research
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
Tuesday Aug 09 2022 at 20:19
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2022 Results – Earnings Call Transcript
Monday May 09 2022 at 22:28
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Troy Wichterman – Chief Financial officer Mike Rice – Chairman and Chief Executive Officer Rod De Greef – President and Chief Operating Officer Conference Call Participants Max Masucci – Cowen and Company Jacob Johnson – Stephens Inc. Thomas Flaten – Lake Street Capital Markets Suraj Kalia – Oppenheimer Operator Welcome to the BioLife Solutions First Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.
Zacks Investment Research
New Strong Sell Stocks for May 2nd
Monday May 02 2022 at 09:02
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
Seeking Alpha
BioLife: Can This Company Successfully Turn Around?
Monday Apr 18 2022 at 15:55
A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company’s growth by acquisition strategy.
Zacks Investment Research
New Strong Sell Stocks for March 31st
Thursday Mar 31 2022 at 08:17
BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.
Seeking Alpha
Temporary Setbacks At BioLife
Wednesday Mar 02 2022 at 15:31
One of its acquired companies, Sterling, could not cope with the rapidly rising demand and this generated substantial one-off costs, marring the figures.
PRNewsWire
BioLife Solutions to Attend and Present at Upcoming Investor Conferences
Tuesday Mar 01 2022 at 08:05
BOTHELL, Wash., March 1, 2022 /PRNewswire/ — BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced Mike Rice, Chairman and CEO, Rod de Greef, President and COO, and Troy Wichterman, CFO, are scheduled to present at both the Cowen and KeyBanc Investor Conferences in March 2022.
Seeking Alpha
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results – Earnings Call Transcript
Monday Feb 28 2022 at 22:15
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results – Earnings Call Transcript
Zacks Investment Research
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
Monday Feb 28 2022 at 19:53
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PRNewsWire
BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022
Monday Feb 21 2022 at 08:03
BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (“CGT”) and broader biopharma markets, today announced the Company’s fourth quarter and full year 2021 financial results will be released after market close on Monday, February 28 th.
Zacks Investment Research
PETQ or BLFS: Which Is the Better Value Stock Right Now?
Friday Feb 11 2022 at 13:05
PETQ vs. BLFS: Which Stock Is the Better Value Option?
MarketBeat
Best Biotech Stocks to Invest in Now
Friday Jan 28 2022 at 12:59
Try your hand at morphing science and business for a great investment opportunity in biotech.
BioLife Solutions Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
BioLife Solutions’s Altman Z-score is 2.99 which is in the gray zone. This indicates a level of ambiguity where further analyses are needed to evaluate the company’s financial stability accurately.
Derived from SEC.GOV filing dataopen_in_new
BioLife Solutions Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 8 insiders have sold $14.42K of common stock in BioLife Solutions on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
BioLife Solutions’s Income Quality of 0.01 is lower than its Industry Group of 0.68 (-98.5% lower)
BioLife Solutions’s Income Quality of 0.01 is lower than its Major Industry Group of 0.71 (-98.6% lower)
BioLife Solutions’s Income Quality of 0.01 is lower than its Sector of 0.75 (-98.7% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
BioLife Solutions’s Current Ratio of 3.04 is in line with its Industry Group of 3.36 (-9.5% lower)
BioLife Solutions’s Current Ratio of 3.04 is in line with its Major Industry Group of 3.13 (-2.9% lower)
BioLife Solutions’s Current Ratio of 3.04 is greater than its Sector of 2.6 (16.9% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-5.9 & -1.02)
Cannot compare a negative PE Ratio (-5.9 & -0.58)
Cannot compare a negative PE Ratio (-5.9 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
BioLife Solutions’s PB Ratio of 1.39 is lower than its Industry Group of 1.9 (-26.8% lower)
BioLife Solutions’s PB Ratio of 1.39 is lower than its Major Industry Group of 1.93 (-28.0% lower)
BioLife Solutions’s PB Ratio of 1.39 is lower than its Sector of 1.62 (-14.2% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
BioLife Solutions’s ROE of -0.24 is in line with its Industry Group of -0.26 (7.7% greater)
BioLife Solutions’s ROE of -0.24 is lower than its Major Industry Group of -0.09 (-166.7% lower)
BioLife Solutions’s ROE of -0.24 is lower than its Sector of -0.03 (-700.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
BioLife Solutions’s ROCE of -0.12 is greater than its Industry Group of -0.27 (55.6% greater)
BioLife Solutions’s ROCE of -0.12 is greater than its Major Industry Group of -0.14 (14.3% greater)
BioLife Solutions’s ROCE of -0.12 is lower than its Sector of -0.04 (-200.0% lower)
Derived from SEC.GOV filing dataopen_in_new